Shak says the study examined the prospective outcomes of 1626 women and showed that at 5 years, less than 1% of women had a distant recurrence.
Steven Shak, MD, chief Scientific Officer, Oncotype Dx, discusses the good news for patients with breast cancer emerging from the NCI-sponsored Trial Assigning Individualized Options for Treatment (Rx), or TAILORx, trial.
The goal of the trial was to examine the effects of chemotherapy in patients with breast cancer who had a midrange recurrent score from 12 to 25. The analysis includes additional single gene results from patients with recurrence scores less than 11 who received hormonal therapy alone.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More